Next Article in Journal
Vesicovaginal Fistulas: Prevalence, Impact, and Management Challenges
Next Article in Special Issue
Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial
Previous Article in Journal
Serotonin Metabolism and Serotonin Receptors Expression Are Altered in Colon Diverticulosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 59
Issue 11
10.3390/medicina59111946
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review

by
Walid Shalata
1,2,*,†,
Zoé Gabrielle Attal
3,
Rajeh Shhadi
2,
Amjad Abu Salman
4,
Ashraf Abu Jama
1,2,
Sondos Shalata
5,
Kais Halumi
1 and
Alexander Yakobson
1,2,†
1
The Legacy Heritage Cancer Center & Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel
2
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel
3
Medical School for International Health, Ben Gurion University of the Negev, Beer Sheva 84105, Israel
4
Cardiology Division, Soroka Medical Center, Beer Sheva 84105, Israel
5
Nutrition Unit, Galilee Medical Center, Nahariya 22000, Israel
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Medicina 2023, 59(11), 1946; https://doi.org/10.3390/medicina59111946
Submission received: 17 September 2023 / Revised: 28 October 2023 / Accepted: 1 November 2023 / Published: 3 November 2023
(This article belongs to the Special Issue Innovations in the Field of Cardio-Oncology)
Browse Figures
Versions Notes

Abstract

Many different types of cancer can be treated with immunotherapy drugs called immune checkpoint inhibitors (ICIs). These drugs have altered the landscape of cancer treatment options since they function by triggering a stronger immune response to malignancy. As expected, ICIs’ modification of immune regulatory controls leads to a wide range of organ/gland-specific immune-related side effects. These adverse effects are uncommonly deadly and typically improve by discontinuing treatment or administering corticosteroid drugs. As a result of a number of factors—including a lack of specificity in the clinical presentation, the possibility of overlap with other cardiovascular and general medical illnesses, difficulties in diagnosis, and a general lack of awareness—the true incidence of ICI-associated myocarditis is likely underestimated. Currently, protocols for the surveillance, diagnosis, or treatment of this condition are unclear. Several questions remain unanswered, such as how to best screen for this rare toxin, what tests should be run on patients who are suspected of having it, how to treat myocarditis once it has developed, and who is at most risk. In this article, we provide a case study of ICI-associated myocarditis and explain its key characteristics and treatment options.
Keywords: myocarditis; cardiac toxicity; inhibitors; immune checkpoint inhibitors (ICIs); immune-related adverse events (IRAE); cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); programmed cell death protein 1 (PD-1); programmed death-ligand 1 (PD-L1) myocarditis; cardiac toxicity; inhibitors; immune checkpoint inhibitors (ICIs); immune-related adverse events (IRAE); cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); programmed cell death protein 1 (PD-1); programmed death-ligand 1 (PD-L1)

Share and Cite

MDPI and ACS Style

Shalata, W.; Attal, Z.G.; Shhadi, R.; Abu Salman, A.; Abu Jama, A.; Shalata, S.; Halumi, K.; Yakobson, A. Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review. Medicina 2023, 59, 1946. https://doi.org/10.3390/medicina59111946

AMA Style

Shalata W, Attal ZG, Shhadi R, Abu Salman A, Abu Jama A, Shalata S, Halumi K, Yakobson A. Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review. Medicina. 2023; 59(11):1946. https://doi.org/10.3390/medicina59111946

Chicago/Turabian Style

Shalata, Walid, Zoé Gabrielle Attal, Rajeh Shhadi, Amjad Abu Salman, Ashraf Abu Jama, Sondos Shalata, Kais Halumi, and Alexander Yakobson. 2023. "Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review" Medicina 59, no. 11: 1946. https://doi.org/10.3390/medicina59111946

APA Style

Shalata, W., Attal, Z. G., Shhadi, R., Abu Salman, A., Abu Jama, A., Shalata, S., Halumi, K., & Yakobson, A. (2023). Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review. Medicina, 59(11), 1946. https://doi.org/10.3390/medicina59111946

Article Metrics

Back to TopTop